Pharmacotherapy Treatment in Substance-Dependent Correctional Populations: A Review

References

• Canadian HIV/AIDS Policy and Law Newsletter. 1996; 2(4), www.aidslaw.ca Accessed Oct. 2003.2001/2002 Prevention and Treatment: Methadone
   Google Scholar
• Ali R., Biggs L., Dorlego B., Gill T., Larkins K., Moyle K., Murray T., Perrin J., Quiqley A., Rysavy P., Sunjic S., Wilson C., Richards I. National Buprenorphine Policy. 2001
   Google Scholar
• American Society of Addiction Medicine. Public policy statement on access to appropriate detoxification services for persons incarcerated in prisons and jails. Journal of Addictive Diseases 2003; 22(3)111–113, [CROSSREF]
   PubMedGoogle Scholar
• Brahen L. S., Capone T. J., Capone D. M. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol 1988; 28(1)64–70, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Brahen L., Capone T., Wiechert V., Desiderio D. Naltrexone and Cyclazocine. Arch Gen Psychiatry 1977; 34: 1181–1184, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brahen L., Henderson R., Capone T., Kordal N. Naltrexone treatment in a jail work-release program. J Clin Psychiatry 1984; 45: 49–52, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Broekhuysen E. S. Methadone. Office of National Drug Control Policy Drug Policy Information Clearinghouse, Washington, DC 2000, www.whitehousedrugpolicy.gov Accessed Sept. 2003
   Google Scholar
• Brooke D., Taylor C., Gunn J., Maden A. Substance misusers remanded to Prison—A treatment opportunity?. Addiction 1988; 93(12)1851–1856, [CROSSREF]
   Google Scholar
• Centre for Evidence Based Mental Health. National Electronic Library for Health (NHS). Department of Psychiatry, University of Oxford, Oxford, UK February, 2002, http://cebmh. warne.ox.ac.uk/cebmh/
   Google Scholar
• Cornish J. W., Metzger D., Woody G., Wilson D., McLellan T., Vandergrift B., O'Brien C. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment 1997; 14(6)529–534, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Darke S., Kaye S., Finlay-Jones R. Drug use and injection risk-taking among prison methadone maintenance patients. Addiction 1998; 93(8)1169–1175, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dolan K. A., Shearer J., MacDonald M., Mattick R., Hall W., Wodak A. D. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian Prison System. Drug and Alcohol Dependence 2003; 72: 59–63, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dolan K., Bryne A. Methadone treatment is widely accepted in prisons in New South Wales. British Medical Journal 1998; 316: 1744, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Dolan K., Hall W., Wodak A. The provisions of methadone within prison settings. Methadone Maintenance Treatment and Other Opioid Replacement Therapies, J. Ward, R. Mattick, et al. Overseas Publishers Association, Harwood Academic Publishers, Amsterdam 1998; 379–396
   Google Scholar
• Dolan K., Wodak A. An international review of methadone provision in prisons. Addiction Research 1996; 4(1)85–97
   Web of Science ®Google Scholar
• Dolan K., Wodak A., Hall W. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review 1998; 17: 153–158, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dolan K., Wodak A., Hall W., Gaughwin M., Rae F. HIV risk behaviour of IDUs before, during and after imprisonment in New South Wales. Addiction Research 1996; 4(2)151–160
   Web of Science ®Google Scholar
• Dolan K., Wodak A., Penny R. AIDS behind bars: Preventing HIV spread among incarcerated drug injectors. AIDS 1995; 9(8)825–832, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Dole V. P., Robinson J. W., Orraca J., Towns E., Searcy P., Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine 1969; 280(25)1372–1375, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Elliot R. Prisoners' Constitutional Right to Clean Needles and Bleach. Canadian HIV/AIDS Policy and Law Newsletter 1995; 2(1), www.aidslaw.ca Accessed Sept. 2003
   Google Scholar
• Federal Bureau of Prisons Clinical Practice Guidelines Detoxification of Chemically Dependent Inmates. The Federal Bureau of Prisons. December, 2000, www.bop.gov/hsdpg/hsdcpgdetoxification.pdf Accessed Sept. 2003.
   Google Scholar
• Gerlach R. Drug-substitution treatment in Germany: a critical overview of its history, legislation and current Practice. Journal of Drug Issues 2002; 503–521, Spring
   Google Scholar
• Hagen H., McGough J. P., Theide H., Weiss N. S., Hopkins S., Alexander E. R. Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology 1999; 149: 203–213
   PubMedGoogle Scholar
• Hammett T. M., Harmon P., Rhodes W. The Burden of Infectious Disease Among Inmates and Releasees from Correctional Facilities. National Commision on Correctional Health Care, National Institute of Justice, Chicago, IL 1999
   Google Scholar
• Herman B. H., Hammock M. K., Arthur-Smith A., Kuehl K., Appelgate K. Effects of acute administration of naltrexone on cardiovascular function body temperature, body weight and serum concentrations of liver enzymes in autistic children. Dev. Pharmacol Ther 1989; 12(3)118–127, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Howells C., Allen S., Gupta J., Stillwell G., Marsden J., Farrell M. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence 2002; 67: 169–176, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Johnson S. L. Impact of institutional methadone maintenance treatment on release outcome. Forum on Correctional Research 2001; 13(3)51–53
   Google Scholar
• Johnson S. L., Van de Ven J., Grant B. A. Institutional Methadone Maintenance Treatment: Impact on Release Outcome and Institutional Behaviour. 2001, http://www.csc-scc.gc.com Accessed Oct. 2003
   Google Scholar
• Joseph H. The Criminal Justice System and Opiate Addiction: A Historical Perspective. NIDA Research Monograph. 1988; 106–125
   Google Scholar
• Jurgens R. Methadone maintenance treatment. Canadian HIV/AIDS Legal Network and Canadian AIDS Society. 1996, www.aidslaw.ca Accessed Sept. 2003
   Google Scholar
• Kinlock T., Battjes R., Schwartz R. The MTC project team. A novel opioid maintenance program for prisoners: preliminary findings. Journal of Substance Abuse Treatment 2002; 22: 141–147, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lo C. C., Stephens R. C. Drugs and prisoners: treatment needs on entering prison. Am. J. Drug Alcohol Abuse 2000; 26(2)229–245, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Magura S., Rosenblum A., Lewis C., Joseph H. The effectiveness of in jail methadone maintenance. Journal of Drug Issues 1993; 23(1)75–99
   Web of Science ®Google Scholar
• Marrazzi M. A., Wroblewski J. M., Kinzie J., Luby E. D. High-dose naltrexone and liver function safety. Am J Addict 1997; 6(1)21–29, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Mason D., Birmingham L., Grubin D. Substance use in remand prisoners: A consecutive case study. BMJ 1997; 315: 18–21, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• McLeod C. Is there a right to methadone treatment in prison?. Canadian HIV/AIDS Policy and Law Newsletter 1996; 2(4), www.aidslaw.ca Accessed Oct. 2003
   Google Scholar
• Menoyo C., Zulaica D., Parras F. Needle Exchange Programs in Prisons In Spain. Canadian HIV/AIDS Policy and Law Review 2000; 5(4), www.aidslaw.ca Accessed Sept. 2003
   PubMedGoogle Scholar
• Mumola C. J. Substance abuse and treatment, state and federal prisoners, 1997. Office of Justice Programs, Washington, DC 1996; 1–16
   Google Scholar
• Nelles J., Fuhrer A., Hirsbrunner H. P., Harding T. W. Provision of syringes: the cutting edge of harm reduction in prison?. BMJ 1998; 317: 270–276, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Paget D. Z. Needle distribution in the Swiss prison setting: a breakthrough?. Canadian HIV/AIDS Policy and Law Newsletter 1995; 2(1), www.aidslaw.ca Accessed Sept. 2003
   Google Scholar
• Parrino M. Methadone Maintenance and Other Pharmacotherapeutic Interventions in the Treatment of Opioid Dependence. National Drug Court Institute, Washington, DC 2002, www.nadcp.org Accessed Oct. 2003
   Google Scholar
• Parrino M. W., McNicholas L. Methadone Maintenance and Other Pharmacotherapeutic Interventions in the Treatment of Opioid Dependence. American Association for the Treatment of Opioid Dependence. 2003, http://www.methadone.org/library/drugcourt.html Accessed Sept. 2003.
   Google Scholar
• Pfohl D. N., Allen J. I., Atkinson R. L., Knopman D. S., Malcolm R. J., Mitchell J. E., Morley J. E. Naltrexone hydrochloride (Trexan): a review of serum transminase elevations at high dosage. NIDA Res Monogr 1986; 67: 66–72, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Pini L. A., Ferretti C., Trenti T., Ferrari A., Sternieri E. Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metabol Drug Interact 1991; 9(2)161–174, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Preston A. Methadone Detoxification: Section 9. The Methdone Briefing. March, 2003, http://www.drugtext.org/library/books/methadone/section9.html. Accessed Sept. 2003
   Google Scholar
• Rawson R. A., Glazer M., Callahan E. J., Liberman R. P. Naltrexone and behavior therapy for heroin addiction. NIDA Res Monograph June, 1979, 25: 26–43
   PubMedGoogle Scholar
• Rothon D. Methadone in Provincial Prisons in British Columbia. Canadian HIV/AIDS Policy and Law Newsletter 1997/98; 3–4(4), www.aidslaw.ca Accessed Oct. 2003
   Google Scholar
• Sax D. S., Kornestsky C., Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol. 1994; 34(9)898–901, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sibbald B. Methadone maintenance expands inside federal prisons. JAMC 2002; 167(10)1154
   PubMed Web of Science ®Google Scholar
• Streeton C., Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized clinical trials. Alcohol and Alcoholism 2001; 36(6)544–552, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Walsh S. L., Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence 2003; 70: S13–S27, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar